Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity. During this study, the investigators will perform either confocal laser endomiscroscopy (CLE) or colonoscopic antigen provocation test (COLAP) to test to which food items the participants react to. Furthermore, the investigators will perform rectal barostat examination and a sigmoidoscopy without laxatives. The investigators will collect biological samples and the participants will complete several questionnaires.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Patients with IBS diagnosis according to their treating physician (ROME IV).

• Association between intake of food and GI symptoms.

• Witnessed written informed consent prior to any study procedures.

• Patients who are capable to understand the study and the questionnaires, and to comply with the study requirements.

Locations
Other Locations
Sweden
Mag-tarmlab, Dept of Internal Medicine, Sahlgrenska University Hospital
RECRUITING
Gothenburg
Contact Information
Primary
Magnus Simrén, MD PhD
magnus.simren@medicine.gu.se
0046313428107
Backup
MagTarmlab office
magtarmlab.su@vgregion.se
0046313428107
Time Frame
Start Date: 2022-08-03
Estimated Completion Date: 2027-01-01
Participants
Target number of participants: 200
Treatments
Other: Positive food item during CLE or COLAP
The food item(s) which were positive during CLE (fluorescein leakage and cell shedding) or COLAP (swelling).
Sponsors
Leads: Magnus Simrén

This content was sourced from clinicaltrials.gov